{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:14:40Z","timestamp":1778710480555,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["114025003"],"award-info":[{"award-number":["114025003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1292\/08"],"award-info":[{"award-number":["CRC 1292\/08"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG CRC 1066\/B3"],"award-info":[{"award-number":["DFG CRC 1066\/B3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["634413"],"award-info":[{"award-number":["634413"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["777377"],"award-info":[{"award-number":["777377"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bcp.2019.113633","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T19:29:35Z","timestamp":1567711775000},"page":"113633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices"],"prefix":"10.1016","volume":"169","author":[{"given":"Emilia","family":"Gore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Bigaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Oldenburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Ook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg F.","family":"Rippmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Boersema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Olinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.113633_b0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.113633_b0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1874312901206010245","article-title":"The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases","volume":"6","author":"Banham-Hall","year":"2012","journal-title":"Open Rheumatol. J."},{"key":"10.1016\/j.bcp.2019.113633_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2019.113633_b0020","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2019.113633_b0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/excr.1996.0053","article-title":"Adhesion mediated by fibronectin\u2019s alternatively spliced EDb (EIIIB) and its neighboring type III repeats","volume":"223","author":"Chen","year":"1996","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2019.113633_b0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3747\/co.22.2393","article-title":"Novel agents and associated toxicities of inhibitors of the pi3k\/Akt\/mtor pathway for the treatment of breast cancer","volume":"22","author":"Chia","year":"2015","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2019.113633_b0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2013.78","article-title":"Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver","volume":"94","author":"Chu","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2019.113633_b0040","first-page":"1","article-title":"Management of adverse events associated with idelalisib treatment \u2013 expert panel opinion","volume":"8194","author":"Coutre","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2019.113633_b0045","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/nprot.2010.111","article-title":"Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies","volume":"5","author":"de Graaf","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2019.113633_b0050","article-title":"Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH","volume":"2","author":"Farrell","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2019.113633_b0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2019.113633_b0060","series-title":"Signaling Pathways in Liver Diseases","author":"Fort","year":"2015"},{"key":"10.1016\/j.bcp.2019.113633_b0065","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1073\/pnas.0906461107","article-title":"Activity of any class IA PI3K isoform can sustain cell proliferation and survival","volume":"107","author":"Foukas","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2019.113633_b0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.67.1.481","article-title":"Phosphoinositide kinases","volume":"67","author":"Fruman","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2019.113633_b0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.113633_b0080","first-page":"5603","article-title":"Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro","volume":"62","author":"Fukuda","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2019.113633_b0085","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/gsk2126458#section=Top."},{"key":"10.1016\/j.bcp.2019.113633_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2019.113633_b0095","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1074\/jbc.M110235200","article-title":"Phosphatidylinositol 3-kinase controls human intestinal epithelial cell differentiation by promoting adherens junction assembly and p38 MAPK activation","volume":"277","author":"Laprise","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.113633_b0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13550-015-0151-x","article-title":"Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging","volume":"5","author":"Li","year":"2015","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.bcp.2019.113633_b0105","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1111\/bph.13945","article-title":"Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis","volume":"174","author":"Luangmonkong","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113633_b0110","doi-asserted-by":"crossref","first-page":"1801992","DOI":"10.1183\/13993003.01992-2018","article-title":"A randomised, placebo-controlled study of omipalisib (PI3K\/mTOR) in idiopathic pulmonary fibrosis","volume":"53","author":"Lukey","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2019.113633_b0115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF","volume":"71","author":"Mercer","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.bcp.2019.113633_b0120","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-15-1665","article-title":"First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies","volume":"22","author":"Munster","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2019.113633_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2013.00002","article-title":"Molecular Interactions between NAFLD and Xenobiotic Metabolism","volume":"4","author":"Naik","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2019.113633_b0130","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2005.06.025","article-title":"Mdr2 (Abcb4)\u2212\/\u2212 mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes","volume":"43","author":"Popov","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2019.113633_b0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin \u03b1v\u03b26 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2019.113633_b0140","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.113633_b0145","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","article-title":"Liver fibrosis: Direct antifibrotic agents and targeted therapies","volume":"68\u201369","author":"Schuppan","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bcp.2019.113633_b0150","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2019.113633_b0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2001-17556","article-title":"Matrix as a modulator of hepatic fibrogenesis","volume":"21","author":"Schuppan","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.bcp.2019.113633_b0160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2019.113633_b0165","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/srep03470","article-title":"HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis","volume":"3","author":"Son","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2019.113633_b0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2019.113633_b0175","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2019.113633_b0185","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrestox.5b00491","article-title":"Classification of cholestatic and necrotic hepatotoxicants using transcriptomics on human precision-cut liver slices","volume":"29","author":"Vatakuti","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2019.113633_b0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tiv.2016.05.012","article-title":"Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis","volume":"35","author":"Westra","year":"2016","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.bcp.2019.113633_b0195","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.taap.2013.11.017","article-title":"Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs","volume":"274","author":"Westra","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113633_b0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/00498254.2012.723151","article-title":"Evaluation of fibrosis in precision-cut tissue slices","volume":"43","author":"Westra","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2019.113633_b0205","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2019.113633_bib207","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:57:50Z","timestamp":1778709470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219303326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":41,"alternative-id":["S0006295219303326"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113633","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113633"}}